Nouscom Presents New Positive Phase 1/2b data of NOUS-209 at SITC 2025, Supporting Plans to Initiate Registration-Enabling Study for Cancer ...
Third quarter revenues up 6% driven by EXPAREL volume growth of 9% -- -- Several key milestones advance 5x30 path to growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback